Eton Pharmaceuticals posts Q3 earnings beat and lifts 2026 revenue outlook
Eton Pharmaceuticals reported third‑quarter 2026 earnings of $0.50 per diluted share, beating consensus estimates by $0.19. Revenue rose to $57.9 million, a 158% year‑over‑year increase. The company also raised its full‑year 2026 revenue guidance to more than $175 million, up from $145 million, citing strong product demand and pipeline progress.
Why it matters
The higher revenue guidance suggests stronger top‑line growth than previously expected, which could support a higher valuation for the stock (the company expects 2026 revenue above $175 million, up from $145 million, per the earnings call). The earnings beat and margin expansion may also improve investor sentiment and attract additional buying pressure.
Key facts
- 1Q3 2026 earnings per diluted share were $0.50, beating estimates by $0.19. investing.com
- 2Quarterly revenue was $57.9 million, up 158% year over year from $22.5 million. tipranks.com
- 3Adjusted EBITDA reached $28.5 million, representing 49% of revenue. tipranks.com
- 4Adjusted gross profit was $46.2 million, yielding an 80% adjusted gross margin. tipranks.com
- 5The company raised its 2026 revenue guidance to more than $175 million, up from $145 million. tipranks.com
- 6Shares jumped over 20% in pre‑market trading following the earnings release. seekingalpha.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.